Bayer AG agreed to settle U.S. lawsuits claiming that its widely-used weed killer Roundup caused cancer for as much as US$10.9 billion after more than a year of talks, resolving litigation that ...

The use of Bayer's contested weed-killer glyphosate, the subject of more than 10,000 lawsuits in the US over claims it causes cancer, will eventually die out, German Chancellor Angela Merkel told ...

A research agronomist at Precision Planting says advancements in sprayer technology are helping farmers improve weed control.

An avalanche of lawsuits filed against Bayer in Missouri is pitting the chemical maker against trial attorneys and cancer patients.

An extension crops educator sees cover crops as a compliment to other weed control tactics. Liz Stahl with the University of Minnesota says herbicides remain the most effective tool for managing weeds ...

In a significant legal ruling, Bayer AG has been ordered by a Washington state jury to pay $100 million to four individuals who claim they suffered health issues due to exposure to polychlorinated ...

Bayer Says It Was Told by Jury to Pay $100 Million Over Toxic Chemicals Trial was the latest over harm tied to school outside Seattle Company vows appeal of verdict and ‘excessive’ damages awarded ...

Although Bayer’s top-selling drug Xarelto lost market exclusivity in most geographies in 2024, the company still predicts it will see strong growth from the pharma business unit beginning in 2027.

Bayer argues PCB levels were safe, blames school for ignoring warnings Previous trials resulted in over $1.5 billion in verdicts Jan 14 (Reuters) - A Washington jury on Tuesday ordered Bayer ...

Bayer AG’s Monsanto unit stopped making toxic PCBs a half century ago, but the legal fallout lingers even as many of the building materials made with the chemicals are no longer used in US homes ...

Bayer’s Monsanto unit stopped making toxic polychlorinated biphenyls (PCBs) a half century ago, but the legal fallout lingers even as many of the building materials made with the chemicals are ...

Bayer’s Parkinson’s disease cell therapy is moving into late-stage testing, with the upcoming trial set to be the first registrational phase 3 study for an investigational allogeneic cell ...